Hakim Djaballah

Hakim Djaballah is a prominent biotechnology executive with extensive experience in developing innovative medical solutions. As the Founder, President, and CEO of Keren Therapeutics since 2016, Hakim leads efforts to create treatments for the side effects of aging, addressing conditions such as muscle fatigue and sarcopenia. In addition, Hakim serves on the Scientific Advisory Board of the Ontario Institute for Cancer Research and has held various advisory roles across several prestigious organizations, including Qurient, Inc., and several Institut Pasteur locations. With a PhD in Biochemistry from the University of Leicester and a BSc (Hons) from the University of Birmingham, Hakim has made significant contributions to oncology and infectious diseases throughout a distinguished career.